SCHEMBL5260609

SCHEMBL5260609

Cc1cc(C)nc(Nc2cc(-c3nc4ccccc4s3)ccc2Cl)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 2/20 0.55
TP53 P04637 2/20 0.52
MAPT P10636 4/20 0.51
APP P05067 5/20 0.50
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
HPGD P15428 2/20 0.48
POLB P06746 1/20 0.48
PTPN7 P35236 1/20 0.48
DUSP3 P51452 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
GLA P06280 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260053 0.88 TP53 (0.63) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL5258486 0.85 SMN1; SMN2 (0.58) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL5263632 0.81 APP (0.63) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL5259397 0.79 SMN1; SMN2 (0.60) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL12963427 0.74 MAPT (0.70) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL12963205 0.74 MAPT (0.74) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL29935542 0.73 KDM4E (0.64) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL2249002 0.72 APP (0.65) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL14156493 0.70 MAPT (0.65) RAB9ASMN1; SMN2NPC1TP53MAPT
SCHEMBL9738354 0.70 RAPGEF4 (0.53) RAB9ASMN1; SMN2NPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 RAB9A 3722/4885SMN1; SMN2 1665/4885NPC1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.